Jeffrey I. Weitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jeffrey I. Weitz has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Alan R. Stafford
From the Hamilton Civic Hospitals Research Centre, and McMaster University, Hamilton, Ontario, Canada L8V 1C3
2 shared publicationsJames C. Fredenburgh
From Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario, L8V 1C3 Canada
2 shared publicationsBeverly Leslie
From the Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada
1 shared publicationDebra L. Becker
Hamilton Civic Hospitals Research Centre, Ontario, Canada
1 shared publicationJim C. Fredenburgh
Hamilton Civic Hospitals Research Centre
1 shared publicationMonika Hudoba
From the Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 1 February 1999
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 41 (2) , 418-432
Prevention of activation of blood coagulation during acute coronary ischemic syndromes beyond aspirin and heparin
Many of the acute coronary ischemic syndromes are triggered by spontaneous or mechanical disruption of atherosclerotic plaques with resultant activation of platelets and coagulation. Given the central role of platelets and thrombin in arterial thrombosis, current strategies for its prevention and treatment focus on both inhibition of platelet aggregation and control of thrombin generation and activity. Although aspirin and unfractionated heparin are the cornerstones of current treatment strategies, both have limitations. This review will describe these limitations and discuss new antithrombotic agents developed for use in acute coronary ischemic syndromes and as adjuncts for percutaneous coronary revascularization procedures.
- 1 February 1999
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 41 (2) , 418-432
Open AccessPrevention of activation of blood coagulation during acute coronary ischemic syndromes beyond aspirin and heparin
Many of the acute coronary ischemic syndromes are triggered by spontaneous or mechanical disruption of atherosclerotic plaques with resultant activation of platelets and coagulation. Given the central role of platelets and thrombin in arterial thrombosis, current strategies for its prevention and treatment focus on both inhibition of platelet aggregation and control of thrombin generation and activity. Although aspirin and unfractionated heparin are the cornerstones of current treatment strategies, both have limitations. This review will describe these limitations and discuss new antithrombotic agents developed for use in acute coronary ischemic syndromes and as adjuncts for percutaneous coronary revascularization procedures.
- Open Access
- 1 July 1998
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 273 (29) , 18292-18299
Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E
- 1 July 1998
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 273 (29) , 18292-18299
Open AccessCharacterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E
- 17 February 1998
- Published by Wolters Kluwer Health in Circulation
- Vol. 97 (6) , 544-552
Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors
Background —Thrombolytic therapy induces a procoagulant state characterized by elevated plasma levels of fibrinopeptide A (FPA), but the responsible mechanism is uncertain. Methods and Results —Washed plasma clots were incubated in citrated plasma in the presence or absence of tissue plasminogen activator (t-PA), and FPA generation was monitored as an index of unopposed thrombin activity. FPA levels are almost twofold higher in the presence of t-PA than in its absence. This primarily reflects the action of thrombin bound to soluble fibrin degradation products because (a) there is progressive FPA generation even after clots are removed from t-PA–containing plasma, and (b) clot lysates produce concentration-dependent FPA generation when incubated in citrated plasma. Using thrombin-agarose affinity chromatography, (DD)E and fragment E but not d -dimer were identified as the thrombin-binding fibrin fragments, indicating that the thrombin-binding site is located within the E domain. Heparin inhibits thrombin bound to fibrin degradation products less effectively than free thrombin. In contrast, D-Phe-Pro-ArgCH 2 Cl, hirudin and hirugen inhibit free thrombin and thrombin bound to fibrin degradation products equally well. Conclusions —Thrombin bound to soluble fibrin degradation products is primarily responsible for the increase in FPA levels that occurs when a clot undergoes t-PA–induced lysis. Like clot-bound thrombin, thrombin bound to fibrin derivatives is protected from inhibition by heparin but susceptible to inactivation by direct thrombin inhibitors. These findings help to explain the superiority of direct thrombin inhibitors over heparin as adjuncts to thrombolytic therapy.
- 17 February 1998
- Published by Wolters Kluwer Health in Circulation
- Vol. 97 (6) , 544-552
Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors
Background —Thrombolytic therapy induces a procoagulant state characterized by elevated plasma levels of fibrinopeptide A (FPA), but the responsible mechanism is uncertain. Methods and Results —Washed plasma clots were incubated in citrated plasma in the presence or absence of tissue plasminogen activator (t-PA), and FPA generation was monitored as an index of unopposed thrombin activity. FPA levels are almost twofold higher in the presence of t-PA than in its absence. This primarily reflects the action of thrombin bound to soluble fibrin degradation products because (a) there is progressive FPA generation even after clots are removed from t-PA–containing plasma, and (b) clot lysates produce concentration-dependent FPA generation when incubated in citrated plasma. Using thrombin-agarose affinity chromatography, (DD)E and fragment E but not d -dimer were identified as the thrombin-binding fibrin fragments, indicating that the thrombin-binding site is located within the E domain. Heparin inhibits thrombin bound to fibrin degradation products less effectively than free thrombin. In contrast, D-Phe-Pro-ArgCH 2 Cl, hirudin and hirugen inhibit free thrombin and thrombin bound to fibrin degradation products equally well. Conclusions —Thrombin bound to soluble fibrin degradation products is primarily responsible for the increase in FPA levels that occurs when a clot undergoes t-PA–induced lysis. Like clot-bound thrombin, thrombin bound to fibrin derivatives is protected from inhibition by heparin but susceptible to inactivation by direct thrombin inhibitors. These findings help to explain the superiority of direct thrombin inhibitors over heparin as adjuncts to thrombolytic therapy.
- Open Access
- 1 October 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (41) , 25493-25499
Evidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin
- 1 October 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (41) , 25493-25499
Open AccessEvidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin
- 1 January 1997
- Published by Springer Nature
- Vol. 425, 55-66
Molecular Basis for the Resistance of Fibrin-Bound Thrombin to Inactivation by Heparin/Serpin Complexes
- 1 January 1997
- Published by Springer Nature
- Vol. 425, 55-66
Molecular Basis for the Resistance of Fibrin-Bound Thrombin to Inactivation by Heparin/Serpin Complexes